Alterity Therapeutics rises on launch of lead drug trial in UK
25/08/2022 13:54
** U.S-listed shares of Alterity Therapeutics Ltd ATHE.O
rise 4.3% to $0.63 premarket
** ATHE launches a mid-stage clinical trial of its lead drug
candidate, ATH434, for the treatment of a rare neurodegenerative
disorder in the United Kingdom urn:newsml:reuters.com:*:nPn5HDKjca
** Says the trial among patients with Multiple System
Atrophy is now open for enrolment
** ATHE's mid-stage study is expected to enroll about 60
adult patients
** Stock was down 16% YTD, up to the last close
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital